Mounting evidence directly indicates aberrant activation of PI3K/AKT and MAPK/ERK1/2 signaling in malignant progression of a variety of human cancers such as human breast carcinoma, lung cancer, lymphomas, leukemias, and malignant melanoma [13,14,15,16]. This evidence concerns the gene MAPK3 and melanoma.